warfarin and paracetamol

Paracetamol can enhance the anticoagulant effect of warfarin. The mechanism is not fully established, but it may involve inhibition of vitamin K epoxide reductase (VKORC1) by paracetamol metabolites, which reduces the synthesis of vitamin K-dependent clotting factors (factors II, VII, IX, X). This effect is additive to warfarin's own inhibition of VKORC1. Additionally, paracetamol may have a direct effect on the INR, possibly via interference with warfarin's metabolism or clearance.

The interaction can cause a significant rise in the international normalised ratio (INR), potentially leading to an increased risk of bleeding. This is particularly relevant with regular paracetamol use, especially at doses above 2 g per day for several consecutive days, or in patients with underlying liver disease or other risk factors for bleeding.

If paracetamol is required, it is advisable to use the lowest effective dose for the shortest duration. Monitor the INR within 3 to 5 days after starting or stopping paracetamol, and regularly during concurrent use (e.g., every 1 to 2 weeks). Consider alternative analgesics if the INR rises significantly or if bleeding occurs. Ensure patient education about signs of bleeding.

Well-established interaction. Recognised in major drug interaction databases and clinical guidelines. Multiple observational studies and case reports have demonstrated an increase in INR with concurrent use, particularly with high doses. The exact mechanism remains an area of research.